Aclaris TherapeuticsvsAmgen

ACRS and AMGN stock compared: price, dividend, valuation and results, from SEC filings.

ACRS

Aclaris Therapeutics, Inc.

$3.44

Value $546M

-1.71%
ACRS's page

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

Aclaris Therapeutics (ACRS) has a market value of $546M and Amgen (AMGN) $235B. Over the last year, with dividends, ACRS moved +39.8% and AMGN +31.5%. Dividend yield: ACRS none, AMGN 2.31%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ACRS$546M

    AMGN$235B

    AMGN is 430 times ACRS

  • Revenue, 12 months

    ACRS$6.4M

    AMGN$38.9B

    AMGN is 6,078 times ACRS

  • Net income, 12 months

    ACRS-$80M

    AMGN$9.4B

  • Operating margin

    ACRS-1,414.0%

    AMGN32.4%

    1,446.4 points apart

  • ROIC

    ACRS-54.3%

    AMGN16.2%

    70.5 points apart

  • P/E

    ACRS–

    AMGN25.0

  • Dividend yield

    ACRS0.0%

    AMGN2.3%

    2.3 points apart

  • 5-year return

    ACRS-75.1%

    AMGN+146.3%

    221.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ACRS-75.1%

AMGN+146.4%

010020020222023202420252026
Returns by period
PeriodACRSWith dividendsAMGNWith dividends
1 year since November 19, 2025+39.8%Price +39.8%+31.5%Price +27.2%
3 years since November 20, 2023+266.0%+54.1% a yearPrice +266.0%+79.2%+21.5% a yearPrice +64.2%
5 years since November 19, 2021-75.1%-24.2% a yearPrice -75.1%+146.3%+19.8% a yearPrice +111.4%
10 years since November 21, 2016-87.3%-18.6% a yearPrice -87.3%+302.7%+14.9% a yearPrice +199.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ACRSAclaris TherapeuticsAMGNAmgen

Valuation

ACRSAMGN
Valuation
Price$3.44$435.64
Market value$546M$235B
Enterprise value (EV)$341M$276B
P/E–25.0
P/E, 5-year median–23.0
P/B3.316.4
EV/EBIT–21.9
Free cash flow yield–4.1%

Results and growth

ACRSAMGN
Results and growth
Revenue, 12 months$6.4M$38.9B
Net income, 12 months-$80M$9.4B
Free cash flow, 12 months-$75M$9.6B
Earnings per share, 12 months-$0.58$17.25
Revenue growth, year on year-58.2%10.0%
Revenue growth a year, past+3.8%over 5 years+7.6%over 5 years
EPS growth a year, past–+2.9%over 5 years

Margins and returns on capital

ACRSAMGN
Margins and returns on capital
Gross margin79.2%70.9%
Operating margin-1,414.0%32.4%
Net margin-1,244.1%24.1%
ROIC-54.3%16.2%
ROE-60.5%87.8%

Balance sheet

ACRSAMGN
Balance sheet
Cash$205M$13.2B
Total debt$1.7M$54.0B
Net debt / EBITDA–2.3
Interest cover–4.8×

Dividends and buybacks

ACRSAMGN
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$10.08
Dividend growth a year, past–+8.1%over 5 years
Buyback yield––
Shareholder yield–2.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ACRS or AMGN

Didn't find what you were looking for?

Ask us
Which is bigger, Aclaris Therapeutics or Amgen?

By market value, Amgen ($235B) is about 430.4 times Aclaris Therapeutics ($546M), at today's prices.

How did ACRS and AMGN stock do over the last 10 years?

Since November 21, 2016, ACRS's price moved -87.3% and AMGN's +199.3%. With dividends: ACRS -87.3% (-18.6% a year), AMGN +302.7% (+14.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, ACRS or AMGN?

The dividend yield at today's price is none for Aclaris Therapeutics and 2.31% for Amgen. Over the last twelve months they paid – and $10.08 per share.

Which has the higher profit margins, Aclaris Therapeutics or Amgen?

Over the last twelve months, the net margin was -1,244.1% for Aclaris Therapeutics and 24.1% for Amgen, and the operating margin -1,414.0% and 32.4%. Revenue was $6.4M and $38.9B.

Which is the better investment, Aclaris Therapeutics or Amgen?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.